BioCryst Pharmaceuticals
BCRX
258 hedge funds and large institutions have $1.26B invested in BioCryst Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 79 increasing their positions, 91 reducing their positions, and 32 closing their positions.
42% more call options, than puts
Call options by funds: $12.1M | Put options by funds: $8.5M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
6% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 32
0% more funds holding
Funds holding: 257 → 258 (+1)
4% less capital invested
Capital invested by funds: $1.32B → $1.26B (-$54.4M)
2.72% less ownership
Funds ownership: 83.67% → 80.95% (-2.7%)
13% less repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 91
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12M |
| 2 |
EP
Eversept Partners
New York
|
+$11M |
| 3 |
BlackRock
New York
|
+$8.95M |
| 4 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$4.11M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.1M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$10.6M |
| 3 |
State Street
Boston,
Massachusetts
|
-$10.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.19M |
| 5 |
Goldman Sachs
New York
|
-$7.81M |
BCRX Hedge Fund Activity: Q4 2024 in Review
258 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2024, worth a combined $1.26B — down 4.1% from $1.32B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new BCRX positions and 32 closed out — a net gain of 2 holders — while 79 added to existing stakes and 91 trimmed.
The largest buyer was Vanguard Group, adding an estimated $12M. The largest seller was T. Rowe Price Associates, cutting an estimated $16.1M.
- 258 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2024, up from 257 in Q3 2024.
- Funds reported $1.26B of BioCryst Pharmaceuticals stock for Q4 2024, down 4.1% quarter-over-quarter.
- 34 funds opened new BioCryst Pharmaceuticals positions in Q4 2024 and 32 closed out, a net change of +2 holders.
- The largest BioCryst Pharmaceuticals buyer in Q4 2024 was Vanguard Group, an estimated $12M added.
- The largest BioCryst Pharmaceuticals seller in Q4 2024 was T. Rowe Price Associates, an estimated $16.1M sold.
Based on aggregated 13F filings for Q4 2024.